Biochemical, serological and microbiological methods have been used to dissect pathogens
and identify the components useful for vaccine development. Although successful in many …

After the development of diagnostic tests for hepatitis A and hepatitis B viruses in the 1970s,
an additional parenterally transmitted agent responsible for the majority of …

Chronic hepatitis C virus (HCV) infection occurs in about 3 percent of the world's population
and is a major cause of liver disease. HCV infection is also associated with …

We discovered that the hepatitis C virus (HCV) envelope glycoprotein E2 binds to human
hepatoma cell lines independently of the previously proposed HCV receptor CD81 …

The mechanisms by which hepatitis C virus (HCV) induces chronic infection in the vast
majority of infected individuals are unknown. Sequences within the HCV E1 and E2 …

Hepatitis C has emerged in recent years as the most common basis for liver disease in the
United States, having infected an estimated 3.9 million people in this country and an …

A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme
variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize …

The conservation of positively charged residues in the N terminus of the hepatitis C virus
(HCV) envelope glycoprotein E2 suggests an interaction of the viral envelope with cell …

Hepatitis C virus (HCV) is a positive sense, single-stranded RNA virus in the Flaviviridae
family. It causes acute hepatitis with a high propensity for chronic infection. Chronic HCV …

Little is known about the role of Abs in determining the outcome of hepatitis C virus (HCV)
infection. By using infectious retroviral pseudotypes bearing HCV glycoproteins, we …